Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 80.31% year-over-year to $9.4 million in Q1 2026; TTM through Mar 2026 was $34.9 million, a 112.84% increase from a year earlier, with the FY2025 full-year figure at $30.7 million, up 139.23% from the prior year.
• Cost of Revenue eased to $9.4 million in Q1 2026 per TARS's latest filing, from $10.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $10.9 million in Q4 2025 and bottomed at $33000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $3.1 million (2024), against an average of $4.0 million.
• Biggest YoY gain for Cost of Revenue was 1766.67% in 2022; the steepest drop was 97.46% in 2022.
• Year by year, Cost of Revenue stood at $400000.0 in 2022, then surged by 204.0% to $1.2 million in 2023, then surged by 305.1% to $4.9 million in 2024, then soared by 121.82% to $10.9 million in 2025, then retreated by 14.01% to $9.4 million in 2026.
• Per Business Quant, the three latest TARS Cost of Revenue figures stand at $9.4 million (Q1 2026), $10.9 million (Q4 2025), and $8.3 million (Q3 2025).